Influence of race and sex on lipoprotein-associated phospholipase A2 levels: Observations from the Dallas Heart Study

Atherosclerosis

Volumn 199, Issue 1, 2008, Pages 110-115

  Brilakis, Emmanouil S ^a,b   Khera, Amit ^a   McGuire, Darren K ^a   See, Raphael ^a   Banerjee, Subhash ^a,b   Murphy, Sabina A ^c   de Lemos, James A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Lipoprotein associated phospholipase A2; Race; Sex factors

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RACE DIFFERENCE; SEX DIFFERENCE; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; CHOLESTEROL, LDL; COHORT STUDIES; CONTINENTAL POPULATION GROUPS; CORONARY ARTERY DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; SEX DISTRIBUTION; TEXAS;

EID: 45249097117     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.10.010     Document Type: Article

References (30)

1. Garza C.A., Montori V.M., McConnell J.P., et al. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc 82 (2007) 159-165
2. Ballantyne C.M., Hoogeveen R.C., Bang H., et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109 (2004) 837-842
3. Koenig W., Khuseyinova N., Lowel H., Trischler G., and Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 110 (2004) 1903-1908
4. Oei H.H., van der Meer I.M., Hofman A., et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 111 (2005) 570-575
5. Brilakis E.S., McConnell J.P., Lennon R.J., et al. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 26 (2005) 137-144
6. Gerber Y., McConnell J.P., Jaffe A.S., et al. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. Arterioscler Thromb Vasc Biol 26 (2006) 2517-2522
7. May H.T., Horne B.D., Anderson J.L., et al. Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am Heart J 152 (2006) 997-1003
8. O'Donoghue M., Morrow D.A., Sabatine M.S., et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation 113 (2006) 1745-1752
9. Ballantyne C.M., Hoogeveen R.C., Bang H., et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 165 (2005) 2479-2484
10. Elkind M.S., Tai W., Coates K., Paik M.C., and Sacco R.L. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 166 (2006) 2073-2080
11. Packard C.J., O'Reilly D.S., Caslake M.J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 343 (2000) 1148-1155
12. Koenig W., Twardella D., Brenner H., and Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 26 (2006) 1586-1593
13. Lanman R.B., Wolfert R.L., Fleming J.K., et al. Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults. Prev Cardiol 9 (2006) 138-143
14. Victor R.G., Haley R.W., Willett D.L., et al. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol 93 (2004) 1473-1480
15. de Lemos J.A., Zirlik A., Schonbeck U., et al. Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol 25 (2005) 2192-2196
16. Khera A., McGuire D.K., Murphy S.A., et al. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 46 (2005) 464-469
17. Abdullah S.M., Khera A., Das S.R., et al. Relation of coronary atherosclerosis determined by electron beam computed tomography and plasma levels of n-terminal pro-brain natriuretic peptide in a multiethnic population-based sample (the Dallas Heart Study). Am J Cardiol 96 (2005) 1284-1289
18. Khera A., de Lemos J.A., Peshock R.M., et al. Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. Circulation 113 (2006) 38-43
19. Wallace T.W., Abdullah S.M., Drazner M.H., et al. Prevalence and determinants of troponin T elevation in the general population. Circulation 113 (2006) 1958-1965
20. Blake G.J., Dada N., Fox J.C., Manson J.E., and Ridker P.M. A prospective evaluation of lipoprotein-associated phospholipase A (2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 38 (2001) 1302-1306
21. Persson M., Nilsson J.A., Nelson J.J., Hedblad B., and Berglund G. The epidemiology of Lp-PLA (2): Distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis (2006)
22. Yamada Y., Yoshida H., Ichihara S., et al. Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis 150 (2000) 209-216
23. Hiramoto M., Yoshida H., Imaizumi T., Yoshimizu N., and Satoh K. A mutation in plasma platelet-activating factor acetylhydrolase (Val279 → Phe) is a genetic risk factor for stroke. Stroke 28 (1997) 2417-2420
24. Yamada Y., Izawa H., Ichihara S., et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 347 (2002) 1916-1923
25. Yamada Y., Metoki N., Yoshida H., et al. Genetic risk for ischemic and hemorrhagic stroke. Arterioscler Thromb Vasc Biol 26 (2006) 1920-1925
26. Ninio E., Tregouet D., Carrier J.L., et al. Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease. Hum Mol Genet 13 (2004) 1341-1351
27. Abuzeid A.M., Hawe E., Humphries S.E., and Talmud P.J. Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe. Atherosclerosis 168 (2003) 283-288
28. Oldgren J., James S.K., Siegbahn A., and Wallentin L. Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. Eur Heart J 28 (2007) 699-704
29. Brilakis E., McConnell J., Lennon R., Meyer J., and Berger P. Lipoprotein-associated phospholipase A2 levels are lower in women compared to men because of a significant negative correlation with HDL cholesterol. Circulation 107 (2003) 45
30. Miyaura S., Maki N., Byrd W., and Johnston J.M. The hormonal regulation of platelet-activating factor acetylhydrolase activity in plasma. Lipids 26 (1991) 1015-1020